Capital Increase in Genmab as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark; November 15, 2022 –Genmab A/S (Nasdaq:GMAB) will increase its share capital by 57,442 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
997 shares at DKK 815.50,
3,175 shares at DKK 939.50,
1,219 shares at DKK 962.00,
9,005 shares at DKK 1,025.00,
3,390 shares at DKK 1,032.00,
197 shares at DKK 1,050.00,
6,282 shares at DKK 1,136.00,
9,200 shares at DKK 1,145.00,
200 shares at DKK 1,147.50,
204 shares at DKK 1,155.00,
1,682 shares at DKK 1,161.00,
2,404 shares at DKK 1,210.00,
2,378 shares at DKK 1,233.00,
16,953 shares at DKK 1,334.50, and
156 shares at DKK 1,408.00.
Proceeds to the company are approximately DKK 66.7 million. The increase corresponds to approximately 0.09% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 2014 of November 1, 2021, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 65,886,724 which is made up of 65,886,724 shares of a nominal value of DKK 1 each, corresponding to 65,886,724 votes.
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: firstname.lastname@example.org
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: email@example.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.
Company Announcement no. 57
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Kalvebod Brygge 43
1560 Copenhagen V
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ministry of Industry and Mineral Resources Announces Details of Third Edition of Future Minerals Forum11.12.2023 19:36:14 CET | Press release
RIYADH, Saudi Arabia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- At a press conference today, the Ministry of Industry and Mineral Resources (MIM) announced details of the third edition of the Future Minerals Forum (FMF), to be held in Riyadh 9th-11th January at the King Abdulaziz International Conference Center. Speaking at the conference, H.E. the Vice Minister for Mining Affairs, Khalid Al-Mudaifer, looked forward to further achievements delivered by the Ministerial Roundtable and FMF 2024. In previous editions, both platforms have seen participation from ministers and a leading group of international speakers to address issues and turn talk into action. The Vice Minister discussed the unique role of the FMF in hosting the only Ministerial Roundtable of its kind in the industry. He said: "We have succeeded in making this meeting a strategic and influential platform led by governments, providing a voice for many countries and official organizations." Over 70 countries will be represented by g
Mendus presenterar positiva överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel som underhållsbehandling vid AML vid ASH-konferensen11.12.2023 19:30:00 CET | Pressemelding
Pressmeddelande Stockholm, 11 december 2023 Per den 24 november 2023 var återfallsfri medianöverlevnad (mRFS) 30,4 månader Medianen för totalöverlevnad (mOS) hade inte ännu inte uppnåtts, med majoriteten av patienterna (14/20) fortfarande i livet Minskning av mätbar av mätbar restsjukdom (MRD) och induktion av immunsvar korrelerar med fördelar för RFS och OS, vilket bekräftar vididencels verkningsmekanism Virtuellt Key Opinion Leader-event (KOL) med huvudprövare för att diskutera nya ASH-data torsdagen den 14 december 2023 kl. 15.00 CET, anmäl här Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, presenterade idag positiva uppdaterade överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel (DCP-001) vid akut myeloid leukemi (AML), vid konferensen American Society of Hematology’s Annual Meeting (ASH 2023). Data från långtidsuppföljningen visade varaktiga behandlingssvar med överlevnadsnytta som överstiger histori
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 202311.12.2023 19:30:00 CET | Press release
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still alive Reduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of action Virtual KOL event with principal investigator to discuss new ASH data on Thursday, December 14, 2023, at 9.00 am ET/3.00 pm CET; register HERE Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel (DCP-001) in acute myeloid leukemia (AML) at the American Society of Hematology’s 65th Annual Meeting (ASH 2023). The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from t
Harbert Management Corporation included in 2023 Pensions & Investments Best Places to Work in Money Management11.12.2023 19:28:04 CET | Press release
BIRMINGHAM, Ala., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) has been voted one of the Best Places to Work in Money Management for the fifth year in a row. Presented by Pensions & Investments, the global news source of money management and institutional investing, the 12th annual survey and recognition program is dedicated to identifying and recognizing the best employers in the money management industry. HMC prides itself on its history of managing the firm and investment strategies with the utmost integrity. For 30 years HMC has been devoted to investing capital in a responsible manner. We are committed to corporate social responsibility and engaging our employees and stakeholders to pursue opportunities that make positive and long-lasting impacts. Investment excellence, transparency with our clients, and exemplary Fund Administration are the hallmarks of HMC’s commitment to investors. “Pensions & Investments is proud to honor the Best Places to Work in
Holding(s) in Company11.12.2023 18:11:50 CET | Press release
TORONTO, Canada, Dec. 11, 2023 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:Amaroq Minerals Ltd.1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):3. Details of person subject to the notification obligationNameAkta sjóðir hf., an alternative investment fund manager and a UCITC management company, acting on behalf of funds operated by the company.City and country of registered office (if applicable)Reykjavík, Iceland4. Full name of sha